Industry Investment Rating - Chemical Pharmaceuticals: No Rating [1] - Traditional Chinese Medicine Production: No Rating [1] - Biopharmaceuticals II: Neutral [1] - Other Medical and Healthcare: Neutral [1] Core Views - The pharmaceutical sector is expected to outperform the CSI 300 Index by 0 70pct with a gain of +0 95% on October 21 2024 [3] - Sub-sectors such as offline pharmacies (+2 57%), medical R&D outsourcing (+1 32%), and medical consumables (+0 77%) performed well, while blood products (-0 36%), hospitals (-0 34%), and pharmaceutical distribution (-0 27%) lagged behind [3] - Top gainers in individual stocks include Changshan Pharmaceutical (+20 01%), Microport (+20 01%), and Guang Sheng Tang (+15 30%), while the biggest losers were Shuo Shi Biological (-4 69%), Yue Kang Pharmaceutical (-4 32%), and Te Bao Biological (-3 95%) [3] Industry News - Johnson & Johnson's PARP inhibitor combination, niraparib and abiraterone, was approved in China for the treatment of metastatic castration-resistant prostate cancer (mCRPC) with BRCA gene mutations [4] Company News - Huahai Pharmaceutical received approval for its Agatroban Injection from the NMPA [4] - Enhua Pharmaceutical received approval for its Clonazepam Injection from the NMPA [4] - Chuanning Biotech reported a 24 43% YoY increase in revenue to 4 456 billion yuan and a 68 07% YoY increase in net profit to 1 076 billion yuan for the first three quarters of 2024 [4] - Salubris reported a 22 18% YoY increase in revenue to 3 001 billion yuan and a 6 70% YoY increase in net profit to 510 million yuan for the first three quarters of 2024 [4] Related Research Reports - Policy updates on equipment renewal are expected to boost medical equipment bidding [3] - GSK's small molecule therapy, Gepotidacin, received FDA priority review [3] - Merck's Sotatercept has been submitted for approval in China for the treatment of PAH [3]
医药行业周报：强生PARP抑制剂组合在华获批上市
Tai Ping Yang·2024-10-22 10:23